Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer-Reference-Cited by-同舟云学术

Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer

Published:2017-06-20 Issue:5 Volume:35 Page:642-648
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Igawa Satoshi,Otani Sakiko,Ryuge Shinichiro,Fukui Tomoya,Nakahara Yoshiro,Hiyoshi Yasuhiro,Ishihara Mikiko,Kusuhara Seiichiro,Harada Shinya,Mitsufuji Hisashi,Kubota Masaru,Sasaki Jiichiro,Masuda Noriyuki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-017-0482-8/fulltext.html

Reference28 articles.

1. Morita T (2002) A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res 93(1):15–23. doi: 10.1111/j.1349-7006.2002.tb01195.x

2. Yamamoto N, Nokihara H, Yamada Y, Shibata T, Tamura Y, Seki Y, Honda K, Tanabe Y, Wakui H, Tamura T (2017) Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Investig New Drugs 35(2):207–216. doi: 10.1007/s10637-016-0411-2

3. Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K (2016) Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Investig New Drugs 34(3):347–354. doi: 10.1007/s10637-016-0347-6

4. Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T (2015) Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Investig New Drugs 33(4):881–889. doi: 10.1007/s10637-015-0243-5

5. Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T (2016) Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Investig New Drugs 34(5):596–603. doi: 10.1007/s10637-016-0371-6

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer

;Cancer Management and Research;2020-06

2. The Clinical Impact of the Post-progression Survival on the Overall Survival in Elderly Patients or Those with a Poor Performance Status and Extensive-disease Small-cell Lung Cancer;Haigan;2020-02-20

3. The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute;Thoracic Cancer;2019-07-27

4. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia;BMC Cancer;2019-02-20

5. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status;Oncology;2018